Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. Flaherty KT, et al. Among authors: dipaola rs. J Clin Oncol. 2015 Jul 20;33(21):2384-91. doi: 10.1200/JCO.2015.60.9727. Epub 2015 Jun 15. J Clin Oncol. 2015. PMID: 26077237 Free PMC article. Clinical Trial.
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Haas NB, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane CJ, Jewett M, Wood L, Wood CG, Atkins MB, Dutcher JJ, Wilding G, DiPaola RS. Haas NB, et al. Among authors: dipaola rs. Clin Cancer Res. 2015 Sep 15;21(18):4048-54. doi: 10.1158/1078-0432.CCR-15-0215. Epub 2015 May 12. Clin Cancer Res. 2015. PMID: 25967143 Free PMC article. Clinical Trial.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Haas NB, et al. Among authors: dipaola rs. Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Lancet. 2016. PMID: 26969090 Free PMC article. Clinical Trial.
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]).
Pili R, Jegede O, Carducci MA, Manola J, Groteluschen DL, Appleman LL, Liu G, Shanks JC, Dakhil SR, Dutcher J, DiPaola RS. Pili R, et al. Among authors: dipaola rs. Clin Genitourin Cancer. 2017 Dec;15(6):642-651.e1. doi: 10.1016/j.clgc.2017.04.023. Epub 2017 Apr 26. Clin Genitourin Cancer. 2017. PMID: 28545998 Free PMC article. Clinical Trial.
Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM. Jilaveanu LB, et al. Among authors: dipaola rs. Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066509 Free PMC article. Clinical Trial.
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Correa AF, et al. Among authors: dipaola rs. J Clin Oncol. 2019 Aug 10;37(23):2062-2071. doi: 10.1200/JCO.19.00107. Epub 2019 Jun 19. J Clin Oncol. 2019. PMID: 31216227 Free PMC article.
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Xu W, et al. Among authors: dipaola rs. Clin Cancer Res. 2019 Oct 15;25(20):6098-6106. doi: 10.1158/1078-0432.CCR-19-0818. Epub 2019 Aug 30. Clin Cancer Res. 2019. PMID: 31471309 Free PMC article.
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Xu W, et al. Among authors: dipaola rs. Clin Cancer Res. 2021 Jun 15;27(12):3397-3403. doi: 10.1158/1078-0432.CCR-21-0025. Epub 2021 Apr 8. Clin Cancer Res. 2021. PMID: 33832947 Free PMC article. Clinical Trial.
251 results